Kos Biotechnology Partners has successfully closed its inaugural fund at $123 million, a landmark achievement for the Greek venture capital landscape. This fund represents the largest debut for any venture capital firm in Greece's history and is one of Europe's most significant first-time life sciences funds. The firm aims to connect US biopharmaceutical expertise and capital with emerging opportunities in Greece and the wider European market.
A Landmark Achievement for Greek Venture Capital
The fund's rapid $123 million (€106 million) closing was accomplished within six months of its December 2025 launch, attracting significant institutional backing. Lead investor Hellenic Development Bank of Investments (HDBI) was an early supporter, joined by a syndicate of global family offices. This milestone not only energizes the life sciences sector but also sets a new record for the largest first-time fundraise across any industry in Greece.
Bridging Transatlantic Expertise
Kos Biotechnology Partners was founded with a clear mission to serve as a strategic bridge between the mature US biopharma ecosystem and Europe's growing scientific talent pool. The firm leverages its presence in key hubs like New York and the Bay Area to provide its portfolio companies with unparalleled access to capital and drug development know-how. This cross-border thesis is further strengthened by an advisory network of prominent Greek diaspora scientists and executives based in the United States.
A Flexible and Strategic Investment Approach
The firm employs a flexible investment strategy, deploying capital across all stages of a company's growth, from seed funding through Series C rounds. Its focus is concentrated on three core subsectors: novel therapeutics, pharmaceutical services, and technology-enabled healthcare platforms. This approach allows Kos to act as a long-term operational partner to innovators who are working to transform human health and redefine standards of care.
The fund has already demonstrated strong momentum with its first investments, including leading a financing round for Epikast, a tech-enabled biopharmaceutical services company. Epikast, headquartered in New York with operations in Athens, perfectly embodies the US-Greece connection that Kos aims to foster. Another strategic investment in a San Francisco-based biotech company is expected to be announced soon, further validating the firm's global strategy.
Leadership with Deep Industry Roots
The firm is led by co-founders Dr. Simos Simeonidis and Alex Tzoukas, who bring a powerful combination of scientific knowledge and financial acumen. Dr. Simeonidis has extensive biomedical training from Columbia and Harvard Medical Schools, complemented by over a decade as a Wall Street biotechnology analyst. His experience includes prominent roles at Morgan Stanley, Sarissa Capital, and Ally Bridge Group, giving him deep insight into both public and private markets.
Alex Tzoukas contributes over a decade of experience in healthcare investment banking and private equity from his time at institutions like Deutsche Bank and Gurnet Point Capital. The leadership team is rounded out by partner Nikos Kostaras, who brings significant operational expertise from his previous role as the country head for Greece at IQVIA. Together, their collective experience provides a robust foundation for guiding portfolio companies from the lab to global markets.
Addressing a Critical Funding Gap
The launch of Kos arrives at a crucial time, addressing a well-documented funding gap between the European and US life sciences sectors. While Europe possesses a strong scientific foundation, many promising biotech companies struggle to secure later-stage financing, often forcing them to seek foreign investment or relocate. Kos aims to build a self-sustaining domestic life sciences investment ecosystem, ensuring that local innovation is supported by dedicated, expert capital.
The successful $123 million closing of Kos Biotechnology Partners' inaugural fund marks a pivotal moment for Greece's innovation ecosystem and the broader European life sciences industry. By combining deep financial expertise with a transatlantic network, the firm is uniquely positioned to cultivate the next generation of biotech leaders. This initiative promises to not only generate significant returns but also to accelerate the development of transformative healthcare solutions on a global scale.